NCAPD2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.23900889548167E-13 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
9.6540999638961E-09 |
Normal-vs-Stage2 |
6.572100E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
8.219400E-03 |
Stage1-vs-Stage2 |
6.729400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
4.437600E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
4.176800E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
4.53860282689789E-11 |
Normal-vs-AfricanAmerican |
4.193900E-02 |
Normal-vs-Asian |
4.555600E-02 |
Caucasian-vs-AfricanAmerican |
5.748800E-01 |
Caucasian-vs-Asian |
4.070400E-01 |
AfricanAmerican-vs-Asian |
8.914200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.58258999999328E-05 |
Normal-vs-Female |
2.53069998290556E-09 |
Male-vs-Female |
6.989800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
2.243800E-03 |
Normal-vs-Extreme_Weight |
2.3387000003261E-08 |
Normal-vs-Obese |
4.001400E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
2.498000E-01 |
Normal_Weight-vs-Obese |
2.102000E-02 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
2.153600E-02 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.322230E-01 |
Normal-vs-Age(41-60Yrs) |
4.270400000006E-05 |
Normal-vs-Age(61-80Yrs) |
6.21100000319785E-08 |
Normal-vs-Age(81-100Yrs) |
3.531600E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.658600E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.741350E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.961000E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.449200E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.008800E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.650200E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
6.953000E-01 |
Normal-vs-Grade 3 |
8.480200E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
5.592300E-02 |
Grade 2-vs-Grade 4 |
6.953000E-01 |
Grade 3-vs-Grade 4 |
8.480200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
4.12669898253171E-11 |
Normal-vs-N1 |
7.062300E-03 |
N0-vs-N1 |
1.010220E-02 |
|
|